Accelerating the development of new therapies
The companies currently hosted within Fogarty Innovation span a wide range of sectors and technologies. However they are all united by a common goal—improving patient care.
While many of our vital signs are easily obtained, the one test that doctors rely on to make the majority of their diagnoses—the blood test—can take hours, if not days, for results. Chronus Health has developed a portable device that provides lab results in minutes, allowing for real-time diagnosis and thus promising to dramatically improve time-to-care and patient outcomes. The startup has focused its initial efforts on complete blood count (CBC) and comprehensive metabolic panel (CMP), which account for 50 percent of all blood tests performed in the United States.
Nonmelanoma skin cancers (NMSC) account for more than 75 percent of all cancers diagnosed in the United States. The current gold standard for diagnosis is biopsy, which requires excision of skin, followed by microscopic evaluation. Biopsies frequently result in scarring, may be painful and increase the risk of infection. Of the 16 million biopsies conducted annually, approximately half do not result in a cancer diagnosis. Enspectra Health is pioneering a new field of virtual biopsies, providing high-resolution images of cellular structures in living skin without the need for an incision. With real-time evaluation across the surface of the skin, Enspectra’s technology holds the potential to reduce unnecessary biopsies and enable earlier and less costly interventions.
As the adoption of telehealth increases, on-demand testing is no longer confined to healthcare settings. Everyplace is aiming to turn any location into a point-of-care lab with a self-service diagnostic kiosk that enables patient-initiated testing in community-based settings. It is designing simple, reliable, contactless patient-initiated testing to facilitate on-demand diagnostics as a complement to telehealth across a range of routine tests. Its platform’s automation and workflow design improves the accessibility of diagnostic testing while ensuring high clinical reliability.
Everyplace’s initial offering is focused on onsite respiratory testing for the post-pandemic workplace, enabling more cost-effective care and timely treatment to reduce flu-related absenteeism.
More than 110 million people worldwide suffer from non-healing, open wounds. High costs and overly complex technology severely limit, if not eliminate, access to advanced wound care technology. Healyx Labs is developing the lowest-cost and easiest-to-use wound vacuum technology for price-sensitive and underserved markets.
One hundred seventy-eight million adults in the United States are missing at least one tooth, and a surprising 40 million are missing all their teeth. Currently, dental implants are the top choice of treatment, yet less than two percent of those impacted by tooth loss are able to reap the benefits due to limited accessibility, high cost, high risk and long treatment time. iDentical is leveraging the latest 3D technology to offer a safer, faster and more affordable solution through its drill-free, non-invasive dental implants.
Approximately 50 percent of all women in the U.S. will suffer symptoms of a pelvic floor disorder resulting from childbirth by the time they turn 55, and over 20 million suffer from pelvic pain. Materna has developed an obstetrics and gynecology (OB-GYN) platform of medical devices: the first, Prep, is aimed at preventing maternal pelvic injuries during childbirth and shortening delivery time; the second, Milli, is helping treat pelvic pain and dyspareunia.
More than 36 million patients in the U.S. suffer from chronic rhinosinusitis. In fact, the condition accounts for 1 to 2% of all physician visits and is associated with $7 to 12 billion in direct U.S. healthcare costs per year. Nasal steroid sprays are typically prescribed as standard of care, but are only partially effective as they cannot reach beyond the anterior portion of the nasal cavity. Maximal medical therapy (sprays and pills) fail in 50% of patients, leaving them with the options of taking repetitive systemic drugs with serious side effects, having expensive, invasive procedures or continuing to suffer without sufficient treatment. Nasus Medical is developing solutions for improved intra-nasal drug delivery through an innovative technology that is designed for patients to treat themselves at home, early in the pathway.